Home Top Movers Aldeyra Therapeutics, Inc. (ALDX) Stock Prices Surge After News of Clinical Trial...

Aldeyra Therapeutics, Inc. (ALDX) Stock Prices Surge After News of Clinical Trial Success

Aldeyra Therapeutics, Inc. (ALDX) stock prices were up 4.81% as of market close on April 26th, 2021 bringing the price per share up to USD$11.11. Subsequent pre-market fluctuations have seen the stock price surge by 21.78%, bringing it up to USD$13.53.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Success of INVIGORATE Clinical Trial

The sharp increase in ALDX stock prices came hot on the heels of the news of positive top-line results from the third phase of INVIGORATE Clinical Trial, reproxalap. The IND designed as a treatment for patients with allergic conjunctivitis was the source of resounding success when the clinical trials successfully achieved statistical significance for its primary endpoint, as well as for every secondary endpoint.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

What’s Next for INVIGORATE?

The company hopes to submit a New Drug Application in the second half of 2021 following a discussion with the U.S. Food and Drug Administration in regard to INVIGORATE results from clinical trials. Current and prospective investors are hopeful that things will go smoothly and the eventual commercialization of reproxalap will bear fruit for both the company and its shareholders.

ALDX’s Public Offering

ALDX announced the completion of its public offering at the beginning of 2021, wherein it put up 7,868,421 shares of its common stock for sale at USD$9.50 per share. Underwriters were also granted the option to purchase up to 1,026,315 shares of common stock in the event of over-allotments. The offering generated USD$74.7 million in gross proceeds with USD$4.7 million in costs associated with the offering. The funds will be allocated primarily to the development of reproxalap, as well as other product candidates.

Funding the Future

In addition to the funds generated from the offering, ALDX has reported having cash and cash equivalents equaling USD$77.9 million as of December 31st 2020. With such a solid liquidity position the company anticipates being able to sustain itself through to the end of 2023, with enough funds to ensure the funding of its many clinical trials currently underway.

Myriad of Clinical Trials Underway

Of the many clinical trials in varying stages of completion, TANQUILITY and TRANQUILITY-2 are clinical trials for the treatment of dry eye disease and are in Phase 3; whereas the GUARD clinical trial I in the first part of its adaptive Phase 3 in proliferative vitreoretinopathy. Furthermore, the company is working on Phase 2 clinical trials of ADX-629 for the treatment of psoriasis, atopic asthma, and, perhaps most significantly, COVID-19.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for ALDX

With hugely successful completion of the INVIGORATE clinical trial, a sound liquidity position, and diversification into the treatment of the global COVID-19 pandemic, ALDX is situated to have a prosperous 2021. Investors are hopeful for the continued success of clinical trials and expect to see the company manage to significantly sustain growth in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Flora Growth Corp. (FLGC) stock declines during premarket. Here’s what you should know?

Flora Growth Corp. (NASDAQ: FLGC) stock gained by 49.67% at last close whereas the FLGC stock price plunged by 18.36% in the pre-market trading...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Drive Shack Inc. (DS) stock soars during after-hour trading, followed by no recent update

Drive Shack Inc. (NASDAQ: DS) stock declined by 3.94% at last close while the DS stock-price surged by 7.38% in the after-hour session. Drive...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Tonix Pharmaceutics Holdings Inc. (TNXP) stock gains during current market. What’s driving it high?

Tonix Pharmaceuticals Holdings Inc. (TNXP) stock gains by 2.81% in the current market trading session. Tonix is a clinical-stage biopharmaceutical business dedicated on finding,...

Intec Pharma Inc. (NTEC) stock declines during current market after a massive upraise. What’s happening?

Intec Pharma Inc. (NASDAQ: NTEC) stock drops by 7.88% during the current market trading session. Intec Pharma is a clinical-stage biopharmaceutical firm specializing in...

Related News

Intec Pharma Inc. (NTEC) stock declines during current market after a massive upraise. What’s happening?

Intec Pharma Inc. (NASDAQ: NTEC) stock drops by 7.88% during the current market trading session. Intec Pharma is a clinical-stage biopharmaceutical firm specializing in...

F5 Networks Inc. (FFIV) stock soars during pre-market trading. Here’s to know why?

F5 Networks Inc. (FFIV) stock gained by 0.23% at the last close while the FFIV stock surged by 6.05% in the pre-market trading session....

Here is why Cerecor Inc. (CERC) stock turnaround in the after-hours on Monday?

Cerecor Inc. (CERC) shares gained 12.23% in after-hours on Monday, July 26, 2021, and closed the trading at $3.12. in the regular trading session,...

Here is why Bit Digital Inc. (BTBT) stock skyrocketed on Monday?

Bit Digital Inc. (BTBT) shares declined 10.94% in after-hours on Monday, July 26, 2021, and closed the day at $7.90. Earlier in the regular...

Why did Protagenic Therapeutics Inc. (PTIX) stock commence the new week with a negative trend?

Protagenic Therapeutics Inc. (PTIX) shares declined 13.82% in the pre-market on Monday, July 26, 2021, as of this writing. In after-hours on Friday, Protagenic...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam